VOR

Vor Biopharma Inc. NASDAQ

Healthcare ·Biotechnology ·US · vorbio.com

$14.71

Mkt Cap $100.8M

52w Low $2.62 19.1% of range 52w High $65.80

50d MA $14.90 200d MA $22.43

P/E (TTM) -0.2x

EV/EBITDA 0.7x

P/B —

Debt/Equity -0.0x

ROE 423.6%

P/FCF -0.9x

RSI (14) —

ATR (14) —

Beta 1.92

50d MA $14.90

200d MA $22.43

Avg Volume 1.0M

About

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted th…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 30, 2026	AMC	-1.14	82.04	+7296.5%	14.70	+1.2%	+21.4%	+18.3%	+22.8%	+10.7%	+14.6%	—
Nov 13, 2025	AMC	-3.06	-3.33	-8.8%	9.75	-2.6%	+2.7%	+2.8%	-6.5%	-19.8%	-29.6%	—
Aug 12, 2025	AMC	-11.40	-43.60	-282.5%	33.20	+24.7%	+21.7%	+19.3%	+28.9%	+22.9%	+23.5%	—
May 14, 2025	AMC	-0.25	-0.26	-4.0%	3.42	-5.3%	+0.0%	+3.5%	+2.6%	+4.4%	+6.7%	—
Mar 20, 2025	AMC	-0.34	-0.44	-29.4%	17.04	-2.6%	+2.1%	+3.8%	-0.5%	-4.9%	-10.1%	—
Nov 7, 2024	AMC	-0.40	-0.40	+0.0%	16.68	-0.1%	+14.9%	+21.1%	+18.6%	+15.0%	+7.6%	—
Aug 8, 2024	AMC	-0.41	-0.41	+0.0%	16.62	-0.1%	-1.3%	-1.4%	-0.1%	-0.7%	+7.8%	—
May 9, 2024	AMC	-0.37	-0.45	-21.6%	36.20	-2.8%	-5.5%	-6.1%	-7.2%	-3.9%	-0.6%	—
Mar 20, 2024	AMC	-0.49	-0.39	+20.4%	36.00	+2.8%	+8.9%	+7.2%	+13.3%	+20.0%	+22.8%	—
Nov 7, 2023	AMC	-0.46	-0.49	-6.5%	39.80	+2.5%	-6.5%	-6.5%	-11.6%	-10.1%	-3.5%	—
Aug 10, 2023	AMC	-0.42	-0.45	-7.1%	51.40	-2.3%	+14.4%	+12.1%	+13.2%	+13.6%	+13.6%	—
May 11, 2023	AMC	-0.38	-0.43	-13.2%	85.80	+0.0%	+0.7%	+3.0%	+7.2%	+5.1%	+1.4%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.87	$16.09	+1.4%	-1.7%	-5.7%	+4.5%	-1.0%	-4.4%
Mar 31	Wedbush	Maintains	Neutral → Neutral	—	$14.70	$14.88	+1.2%	+21.4%	+18.3%	+22.8%	+10.7%	+14.6%
Dec 19	JP Morgan	Maintains	Overweight → Overweight	—	$12.80	$12.92	+0.9%	-3.0%	+7.1%	+5.7%	+13.5%	+15.0%
Nov 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.75	$9.50	-2.6%	+2.7%	+2.8%	-6.5%	-19.8%	-29.6%
Oct 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$26.93	$26.79	-0.5%	-5.3%	-7.2%	-10.5%	-16.8%	-23.7%
Oct 15	Baird	Upgrade	Neutral → Outperform	—	$30.81	$32.93	+6.9%	-1.9%	-5.7%	-5.9%	-4.5%	-9.9%
Aug 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$40.40	$39.40	-2.5%	-2.0%	+5.9%	+1.0%	+1.5%	+8.9%
Jun 30	HC Wainwright & Co.	Upgrade	Neutral → Buy	—	$21.20	$22.40	+5.7%	+52.8%	+34.9%	+36.8%	+80.2%	+151.9%
Jun 27	Baird	Maintains	Neutral → Neutral	—	$17.80	$18.77	+5.4%	+19.1%	+82.0%	+60.7%	+62.9%	+114.6%
Jun 26	Wedbush	Maintains	Neutral → Neutral	—	$11.09	$20.00	+80.3%	+60.5%	+91.2%	+192.2%	+157.9%	+161.5%
May 9	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$3.20	$3.20	+0.0%	-5.3%	+7.8%	+0.0%	+6.9%	+6.9%
May 9	JMP Securities	Downgrade	Market Outperform → Market Perform	—	$3.20	$3.20	+0.0%	-5.3%	+7.8%	+0.0%	+6.9%	+6.9%
Mar 21	Stifel	Maintains	Buy → Buy	—	$17.04	$16.60	-2.6%	+2.1%	+3.8%	-0.5%	-4.9%	-10.1%
Mar 21	Oppenheimer	Maintains	Outperform → Outperform	—	$17.04	$16.60	-2.6%	+2.1%	+3.8%	-0.5%	-4.9%	-10.1%
Mar 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.04	$16.60	-2.6%	+2.1%	+3.8%	-0.5%	-4.9%	-10.1%
Dec 10	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$20.80	$21.00	+1.0%	-2.9%	-5.8%	-6.0%	-4.7%	-1.9%
Dec 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$20.80	$21.00	+1.0%	-2.9%	-5.8%	-6.0%	-4.7%	-1.9%
Nov 8	Baird	Maintains	Outperform → Outperform	—	$16.68	$16.66	-0.1%	+14.9%	+21.1%	+18.6%	+15.0%	+7.6%
Nov 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.68	$16.66	-0.1%	+14.9%	+21.1%	+18.6%	+15.0%	+7.6%
Sep 6	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$16.50	$19.18	+16.2%	+10.1%	+32.1%	+33.3%	+28.5%	+27.3%
Sep 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.50	$19.18	+16.2%	+10.1%	+32.1%	+33.3%	+28.5%	+27.3%
Aug 14	Barclays	Maintains	Overweight → Overweight	—	$16.60	$16.42	-1.1%	-0.6%	+7.9%	+14.6%	+14.5%	+19.3%
May 13	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$34.20	$35.60	+4.1%	-0.6%	-1.8%	+1.8%	+5.3%	+5.8%
May 13	Oppenheimer	Maintains	Outperform → Outperform	—	$34.20	$35.60	+4.1%	-0.6%	-1.8%	+1.8%	+5.3%	+5.8%
May 10	Wedbush	Maintains	Outperform → Outperform	—	$36.20	$35.20	-2.8%	-5.5%	-6.1%	-7.2%	-3.9%	-0.6%
Apr 23	Wedbush	Maintains	Outperform → Outperform	—	$36.40	$37.00	+1.6%	+3.3%	-4.4%	-6.6%	-7.1%	-4.4%
Mar 22	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$39.20	$39.80	+1.5%	-1.5%	+4.1%	+10.2%	+12.8%	+20.9%
Mar 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$36.00	$37.00	+2.8%	+8.9%	+7.2%	+13.3%	+20.0%	+22.8%
Mar 21	Wedbush	Maintains	Outperform → Outperform	—	$36.00	$37.00	+2.8%	+8.9%	+7.2%	+13.3%	+20.0%	+22.8%
Mar 21	Oppenheimer	Maintains	Outperform → Outperform	—	$36.00	$37.00	+2.8%	+8.9%	+7.2%	+13.3%	+20.0%	+22.8%
Mar 21	Stifel	Maintains	Buy → Buy	—	$36.00	$37.00	+2.8%	+8.9%	+7.2%	+13.3%	+20.0%	+22.8%
Jan 18	Wedbush	Maintains	Outperform → Outperform	—	$46.00	$46.20	+0.4%	+7.4%	-1.3%	+4.3%	+1.7%	+1.7%
Aug 14	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$58.80	$57.60	-2.0%	-2.0%	-1.0%	-0.7%	-0.7%	-0.3%
Aug 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$51.40	$50.20	-2.3%	+14.4%	+12.1%	+13.2%	+13.6%	+13.6%
Aug 11	Wedbush	Maintains	Outperform → Outperform	—	$51.40	$50.20	-2.3%	+14.4%	+12.1%	+13.2%	+13.6%	+13.6%
Jun 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$100.00	$100.00	+0.0%	-1.6%	+3.2%	+2.0%	-2.8%	+1.4%
May 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$88.40	$91.80	+3.8%	+4.1%	+2.0%	-1.6%	+0.7%	+12.2%
May 16	JonesTrading	Maintains	Buy → Buy	—	$88.40	$91.80	+3.8%	+4.1%	+2.0%	-1.6%	+0.7%	+12.2%
May 15	Oppenheimer	Maintains	Outperform → Outperform	—	$86.40	$88.20	+2.1%	+2.3%	+6.5%	+4.4%	+0.7%	+3.0%
May 12	Wedbush	Maintains	Outperform → Outperform	—	$85.80	$85.80	+0.0%	+0.7%	+3.0%	+7.2%	+5.1%	+1.4%
Mar 24	Oppenheimer	Maintains	Outperform → Outperform	—	$102.00	$101.20	-0.8%	+15.3%	+10.2%	+7.6%	+4.1%	+2.7%
Mar 24	Baird	Maintains	Outperform → Outperform	—	$102.00	$101.20	-0.8%	+15.3%	+10.2%	+7.6%	+4.1%	+2.7%
Mar 24	Stifel	Maintains	Buy → Buy	—	$102.00	$101.20	-0.8%	+15.3%	+10.2%	+7.6%	+4.1%	+2.7%
Mar 24	JMP Securities	Maintains	Market Outperform → Outperform	—	$102.00	$101.20	-0.8%	+15.3%	+10.2%	+7.6%	+4.1%	+2.7%
Mar 24	Truist	Maintains	Buy → Buy	—	$102.00	$101.20	-0.8%	+15.3%	+10.2%	+7.6%	+4.1%	+2.7%
Feb 13	JMP Securities	Maintains	Market Outperform → Outperform	—	$110.80	$109.60	-1.1%	-3.8%	-5.8%	+3.2%	-3.4%	+5.6%
Jan 19	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$112.80	$113.40	+0.5%	-3.9%	-0.7%	-2.3%	-5.5%	-3.0%
Nov 14	Oppenheimer	Maintains	Outperform → Outperform	—	$83.60	$84.00	+0.5%	+2.9%	+10.3%	+7.7%	+8.4%	+2.2%
Nov 11	Barclays	Maintains	Overweight → Overweight	—	$79.60	$78.60	-1.3%	+5.0%	+8.0%	+15.8%	+13.1%	+13.8%
Aug 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$108.00	$105.00	-2.8%	-0.2%	-2.6%	-6.1%	-5.4%	-8.7%

Recent Filings

8-K · 5.02 !!! Very High

Voyager Therapeutics, Inc. -- 8-K 5.02: Executive Change

Voyager Therapeutics replaced CFO Nathan Jorgensen while elevating Robin Swartz to COO and adding Amy Quinlan as director, signaling operational restructuring effective May 2026.

Apr 21

8-K · 1.01 ! Medium

Unknown — 8-K 1.01: Equity Issuance

VOR's private equity placement dilutes existing shareholders but provides necessary capital for growth or operational needs, which could pressure the stock short-term while enabling long-term value creation.

Mar 27

Data updated apr 27, 2026 8:00am · Source: massive.com